Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals - ECDC PPS validation protocol version 3.1.2.
This protocol version is an accompanying document to the ECDC protocol for the point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals version 5.3.
Surveillance systems overview for 2017
This spreadsheet contains all surveillance system overview tables from ECDC's annual epidemiological report for 2017.
- Chlamydia infection
- Crimean-Congo haemorrhagic fever
- Ebola haemorrhagic fever
- hantavirus infection
- healthcare-associated infections
- hepatitis A
- hepatitis B
- hepatitis C
- HIV infection
- invasive Haemophilus influenzae disease
- Lassa fever
- Marburg haemorrhagic fever
- meningococcal disease
- pneumococcal disease
- Q fever
- Rift Valley fever
- severe acute respiratory syndrome
- surgical site infections
- verotoxigenic Escherichia coli infection
- West Nile fever
- yellow fever
Infographic: Healthcare-associated infections – a threat to patient safety in Europe
A total of 8.9 million healthcare-associated infections were estimated to occur each year in European hospitals and long-term care facilities.
Antimicrobial use in European long-term care facilities: results from the third point prevalence survey of healthcare-associated infections and antimicrobial use, 2016 to 2017
Ricchizzi, E., Latour, K., Kärki, T., Buttazzi, R., Jans, B., Moro, M.L., Nakitanda, O.A., Plachouras, D., Monnet, D.L., Suetens, C., Kinross, P., The Halt Study Group
Antimicrobial use in European acute care hospitals: results from the second point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use, 2016 to 2017
Plachouras, D., Kärki, T., Hansen, S., Hopkins, S., Lyytikäinen, O., Moro, M.L., Reilly, J., Zarb, P., Zingg, W., Kinross, P., Weist, K., Monnet, D.L., Suetens, C., The Point Prevalence Survey Study Group
Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017
Suetens, C., Latour, K., Kärki, T., Ricchizzi, E., Kinross, P., Moro, M.L., Jans, B., Hopkins, S., Hansen, S., Lyytikäinen, O., Reilly, J., Deptula, A., Zingg, W., Plachouras, D., Monnet, D.L., The Healthcare-Associated Infections Prevalence Study Group
Infographic: Antibiotic resistance – an increasing threat to human health
Each year, 33000 people die from an infection due to bacteria resistant to antibiotics. The burden of infections with bacteria resistant to antibiotics on the European population is comparable to that of inﬂuenza, tuberculosis and HIV/AIDS combined.
Healthcare-associated pneumonia in acute care hospitals in European union/European economic area countries: An analysis of data from a point prevalence survey, 2011 to 2012
Walter, J., Haller, S., Quinten, C., Kärki, T., Zacher, B., Eckmanns, T., Abu Sin, M., Plachouras, D., Kinross, P., Suetens, C., Strauss, R., Mertens, K., Dobreva, E., Budimir, A., Hadjiloucas, A., Prattingerová, J., Kristensen, B., Monnet, D.L., Märtin, P., Lyytikäinen, O., Giard, M., Piening, B., Kritsotakis, E.I., Kurcz, A., Gudlaugsson, Ó., Burns, K., Moro, M.L., Dumpis, U., Ašembergienė, J., Heisbourg, E., Xuereb, D., Hopmans, T., Sorknes, N.K., Deptuła, A., Paiva, J.-A., Serban, R., Litvová, S., Kolman, J., Lozano, J., Struwe, J., Hopkins, S., Doherty, L., Reilly, J.S., Harrison, W.
Rapid risk assessment: Carbapenemase-producing (OXA-48) Klebsiella pneumoniae ST392 in travellers previously hospitalised in Gran Canaria, Spain
This rapid risk assessment evaluates the risk of transmission and further spread of OXA-48-producing Klebsiella pneumonia e ST392 from travellers having sought medical care in Gran Canaria to healthcare facilities in their country of origin in the EU/EEA.
Rapid risk assessment: Emergence of resistance to ceftazidime-avibactam in carbapenem-resistant Enterobacteriaceae
This risk assessment will discuss CAZ-AVI resistance in brief, review the recent literature reporting resistance of CRE to CAZ-AVI, and assess the risk for the EU/EEA countries.